News >

Triplet Regimen Active Against Relapsed/Refractory Pediatric AML

Jason Harris
Published: Tuesday, Oct 24, 2017

Yoav Messinger, MD

Yoav Messinger, MD
The combination of clofarabine, cyclophosphamide, and etoposide (CCE) reached an overall response rate of 41% in a small study of children and adolescents with relapsed/refractory acute myeloid leukemia (AML).

colitis, enterococcus sepsis and culture negative sepsis, and viridans streptococcus.
Messinger Y, Boklan J, Goldberg J, et al. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatr Hematol Oncol [published online October 17, 2017]. doi: 10.1080/08880018.2017.1360970.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x